Immunotherapy

A Houston-area biotech company will expand indications of its investigational and proprietary biologic combination therapy beyond amyotrophic lateral sclerosis to include frontotemporal dementia and Parkinson’s disease.

Wafik S. El-Deiry, MD, PhD, FACP, has been elected chair of the Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine Association — WIN Consortium.

A preclinical study conducted at the Icahn School of Medicine at Mount Sinai has found an allergy pathway that, when blocked, triggers antitumor immunity in mouse models of non-small cell lung cancer.

WAILEA, Hawaii — The world of melanoma has changed a lot in recent years and more change is yet to come, according to a speaker at Hawaiian Eye 2024.

Sarah L. Sammons, MD, was 7 when her mother was diagnosed with breast cancer.

The Advanced Research Projects Agency for Health, or ARPA-H, awarded $45 million to fast track the development of a “closed loop” implant for continuous monitoring of patients with cancer undergoing treatment with immunotherapy.

Results of a phase 1 trial for a vaccine targeting micrometastatic disease markers in patients already treated for pancreatic or colorectal cancer showed potential in preventing recurrence, according to a study in Nature Medicine.

The phase 2 clinical trial of Verrica’s peptide-based immunotherapy trial for basal cell carcinoma has enrolled and dosed its final patient, the company announced in a press release.

Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.

Adding sintilimab to chemotherapy improved survival compared with placebo among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, phase 3 study results published in JAMA showed.